Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.2K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Chemical Synapses01:26

Chemical Synapses

9.0K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.0K
Muscle Contraction01:10

Muscle Contraction

6.6K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.6K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

17
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
17

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metrnl and macrophage polarization: role in skeletal muscle homeostasis and therapeutic potential.

Frontiers in immunology·2026
Same author

Erector spinae plane block versus paravertebral block for pediatric percutaneous nephrolithotomy: interpreting procedural time and statistical non-significance.

Brazilian journal of anesthesiology (Elsevier)·2026
Same author

Myasthenia Gravis and Thymoma.

Muscle & nerve·2026
Same author

Spinal neuromotor rehabilitation using a portable isokinetic training robot.

Nature·2026
Same author

Impact of corticosteroid use on comorbidities in patients with myasthenia gravis in the US National Veterans Affairs Health Network.

Journal of the neurological sciences·2026
Same author

Analysis of infections and malignancy risks among patients with myasthenia gravis compared with matched controls in a US real-world setting.

Journal of neuromuscular diseases·2026

Related Experiment Video

Updated: Aug 12, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K

Myasthenia gravis: Frequently asked questions.

John A Morren1, Yuebing Li2

  • 1Staff, Neuromuscular Center, and Program Director, Neuromuscular Medicine Fellowship, Neurological Institute, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.

Cleveland Clinic Journal of Medicine
|February 1, 2023
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis is an autoimmune disorder affecting neuromuscular junctions, causing fatigable muscle weakness. Treatment is individualized, involving medications, immunotherapy, and surgery.

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.4K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

831

Related Experiment Videos

Last Updated: Aug 12, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.4K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

831

Area of Science:

  • Neurology
  • Immunology

Background:

  • Myasthenia gravis is an autoimmune disorder impacting neuromuscular junction transmission.
  • It is characterized by antibodies targeting the post-synaptic membrane.
  • Clinical presentation includes fatigable skeletal muscle weakness, varying in severity and location.

Purpose of the Study:

  • To provide an up-to-date, clinically relevant review of myasthenia gravis.
  • To offer high-yield information in a question-and-answer format.
  • To guide individualized treatment strategies for myasthenia gravis patients.

Main Methods:

  • Literature review utilizing a question-and-answer format.
  • Synthesis of current clinical knowledge on myasthenia gravis.
  • Focus on practical, evidence-based information for clinicians.

Main Results:

  • Myasthenia gravis results from antibodies disrupting neuromuscular transmission.
  • Pyridostigmine, immunotherapy, and thymectomy are primary treatment modalities.
  • Treatment decisions are personalized based on disease factors.

Conclusions:

  • Effective management of myasthenia gravis requires understanding its autoimmune basis and varied clinical course.
  • Individualized treatment plans are crucial for optimal patient outcomes.
  • This review serves as a valuable resource for clinicians managing myasthenia gravis.